Floatz logo

Tas-102

Myelodysplastic Syndrome With Isolated Del(5q)

National Cancer Institute (NCI)unclassifiedPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Myelodysplastic Syndrome With Isolated Del(5q) cohort.

Asset / SponsorPhaseRating
Cediranib
Mayo Clinic
Phase 3BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
Mayo Clinic
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 3BB

View all 22 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →